Literature DB >> 20512084

SH3GL2 gene participates in MEK-ERK signal pathway partly by regulating EGFR in the laryngeal carcinoma cell line Hep2.

Chao Shang1, Yan Guo, Shuang Fu, Weineng Fu, Kailai Sun.   

Abstract

BACKGROUND: The human Src homology 3 (SH3) domain GRB2-like 2 (SH3GL2) gene, a novel tumor suppressor gene in laryngeal squamous cell carcinoma (LSCC), induces apoptosis of tumor cells by regulating intra-cellular signal transduction networks. The objective of this study was to investigate the molecular mechanism of SH3GL2 in laryngeal carcinogenesis. MATERIAL/
METHODS: RNA interference inhibited the expression of level of SH3GL, and RT-PCR and Western blotting were applied to evaluate the expression level of SH3GL2 after RNA interference. After RNA interference, flow cytometry and 3-(4,5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay were used to detect the biological effects, and Western blotting was used to determine the expression of EGFR and phosphorylated ERK1/2. The Hep2 cells transfected with siRNA-SH3GL2 were treated by U0126 (selective MEK1/2 Inhibitor), and the phosphorylated ERK1/2 proteins were detected by Western blotting; cell proliferation and apoptosis were detected subsequently.
RESULTS: Our results show that the expression level of epidermal growth factor receptor (EGFR) and phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2) were up-regulated after down-regulation of SH3GL2. Additionally, SH3GL2 promoted apoptosis while decreasing cell proliferation. However, if ERK1/2 was inhibited by U0126, the apoptosis rate increased and proliferation decreased inversely.
CONCLUSIONS: SH3GL2 participates in the regulation of apoptosis through the MEK-ERK signal pathway by adjusting EGFR in the laryngeal carcinoma cell line Hep2.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512084

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  7 in total

1.  A combined modality of carboplatin and photodynamic therapy suppresses epithelial-mesenchymal transition and matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in HEp-2 human laryngeal cancer cells via ROS-mediated inhibition of MEK/ERK signalling pathway.

Authors:  Wenjing Mao; Yan Sun; Huankang Zhang; Luhong Cao; Jiajia Wang; Peijie He
Journal:  Lasers Med Sci       Date:  2016-08-01       Impact factor: 3.161

Review 2.  Influenza virus and cell signaling pathways.

Authors:  Pratibha Gaur; Ashok Munjhal; Sunil K Lal
Journal:  Med Sci Monit       Date:  2011-06

3.  MicroRNA-330 is an oncogenic factor in glioblastoma cells by regulating SH3GL2 gene.

Authors:  Shengtao Qu; Yilong Yao; Chao Shang; Yixue Xue; Jun Ma; Zhen Li; Yunhui Liu
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

4.  Loss of SH3GL2 promotes the migration and invasion behaviours of glioblastoma cells through activating the STAT3/MMP2 signalling.

Authors:  Yufu Zhu; Xiang Zhang; Lei Wang; Zhe Ji; Manyi Xie; Xinyu Zhou; Zhiyi Liu; Hengliang Shi; Rutong Yu
Journal:  J Cell Mol Med       Date:  2017-05-04       Impact factor: 5.310

5.  Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.

Authors:  Guru Prasad Maiti; Pinaki Mondal; Nupur Mukherjee; Amlan Ghosh; Susmita Ghosh; Sanjib Dey; Jayanta Chakrabarty; Anup Roy; Jaydip Biswas; Susanta Roychoudhury; Chinmay Kumar Panda
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

6.  Genome-Wide Loss of Heterozygosity and DNA Copy Number Aberration in HPV-Negative Oral Squamous Cell Carcinoma and Their Associations with Disease-Specific Survival.

Authors:  Chu Chen; Yuzheng Zhang; Melissa M Loomis; Melissa P Upton; Pawadee Lohavanichbutr; John R Houck; David R Doody; Eduardo Mendez; Neal Futran; Stephen M Schwartz; Pei Wang
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

7.  MiR-330-mediated regulation of SH3GL2 expression enhances malignant behaviors of glioblastoma stem cells by activating ERK and PI3K/AKT signaling pathways.

Authors:  Yilong Yao; Yixue Xue; Jun Ma; Chao Shang; Ping Wang; Libo Liu; Wenjing Liu; Zhen Li; Shengtao Qu; Zhiqing Li; Yunhui Liu
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.